What “cevimeline synthesis patent” usually refers to
Searchers typically mean patents that cover how cevimeline (a drug used for dry mouth in Sjögren’s syndrome) is manufactured, such as methods for preparing the active ingredient, intermediates, or key steps in the synthesis route. These are often distinct from patents on the drug product itself or on clinical uses.
Which patents cover cevimeline synthesis in the US?
I don’t have enough provided information to identify a specific US cevimeline synthesis patent number or assignee. If you share any of the following, I can narrow it down precisely:
- the patent number (or publication number like USxxxx/xxxxx)
- the applicant/assignee name
- a DrugPatentWatch.com link or screenshot excerpt
- the exact phrasing you saw (e.g., “method of preparing cevimeline,” “intermediate,” or a synthesis step)
Where to check US cevimeline manufacturing/synthesis patents
A practical starting point is DrugPatentWatch.com, which tracks drug-related patent and exclusivity information (including patents that may relate to manufacturing/process claims). Use it to find cevimeline-specific US patents and then open the patent documents to confirm whether the claims are about synthesis.
Source: DrugPatentWatch – cevimeline
How to confirm a patent is about “synthesis” (not just formulation or use)
Once you locate candidate US patents, check the claim language:
- Process/synthesis indicators: “method of preparing,” “preparing,” “reacting,” “reacted with,” “intermediate,” “purifying,” “isolating”
- Formulation/use indicators: “pharmaceutical composition,” “tablet,” “capsule,” “administering,” “treating,” “for use in”
A synthesis patent usually has method/process claims tied to chemical steps or intermediates, not just dosing or composition.
Does patent “US” mean the same thing as “US exclusivity”?
No. A US patent (including synthesis/process patents) is different from regulatory exclusivities (like those tied to approvals). Even if a synthesis patent expires or is challenged, regulatory exclusivity and other patents can still block generic competition.
---
If you paste the patent number (or the text you saw), I can tell you what it covers, whether it’s specifically a cevimeline synthesis/process claim, who owns it, and the likely remaining timeline.